Angela Henkensiefken

Title: Angela Henkensiefken: Innovator in Bispecific Antibody Technology

Introduction

Angela Henkensiefken is a prominent inventor based in San Jose, CA. She has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibody constructs. Her innovative work has the potential to advance therapeutic strategies in various medical applications.

Latest Patents

Angela holds a patent for "HER-2 targeted bispecific compositions and methods for making and using the same." This patent discloses polypeptides and methods that involve a bispecific antibody construct covalently linked to an extended recombinant polypeptide. The design includes a barcode fragment that is releasable upon digestion by a protease, along with a Release Segment that can be proteolytically cleaved. This innovative approach allows for the bispecific antibody construct to be released from the extended recombinant polypeptide, showcasing her expertise in antibody technology.

Career Highlights

Angela is currently employed at Amunix Pharmaceuticals, Inc., where she continues to push the boundaries of biopharmaceutical research. Her work is characterized by a commitment to developing novel therapeutic solutions that address unmet medical needs. With her background and expertise, she has become a valuable asset to her team and the broader scientific community.

Collaborations

Angela collaborates with notable colleagues, including Volker Schellenberger and Eric Johansen. These partnerships enhance her research efforts and contribute to the advancement of innovative biotechnological solutions.

Conclusion

Angela Henkensiefken is a trailblazer in the field of bispecific antibody technology, with a patent portfolio that reflects her innovative spirit. Her work at Amunix Pharmaceuticals, Inc. and collaborations with esteemed colleagues position her as a key figure in the biotechnology landscape.